Compile Data Set for Download or QSAR
Report error Found 34 Enz. Inhib. hit(s) with all data for entry = 11319
TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606867(US11685738, Compound A3)
Affinity DataIC50: 0.570nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606865(US11685738, Compound A4)
Affinity DataIC50: 1.40nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606917(US11685738, Compound A23)
Affinity DataIC50: 4.30nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606955(US11685738, Compound A21-2)
Affinity DataIC50: 4.60nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606865(US11685738, Compound A4)
Affinity DataIC50: 5.69nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606947(US11685738, Compound A15s)
Affinity DataIC50: 5.92nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606954(US11685738, Compound A21 | acid )
Affinity DataIC50: 7.64nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606883(US11685738, Compound A6)
Affinity DataIC50: 8.25nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606864(US11685738, Compound A1)
Affinity DataIC50: 8.30nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606866(US11685738, Compound A2)
Affinity DataIC50: 9nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606947(US11685738, Compound A15s)
Affinity DataIC50: 9.28nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM50134778((S)-3-(6-Methoxy-pyridin-3-yl)-3-{2-oxo-3-[3-(5,6,...)
Affinity DataIC50: 9.57nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606881(US11685738, Compound A5)
Affinity DataIC50: 9.97nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606884(US11685738, Compound A7)
Affinity DataIC50: 11.6nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606866(US11685738, Compound A2)
Affinity DataIC50: 11.6nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606864(US11685738, Compound A1)
Affinity DataIC50: 13.2nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606917(US11685738, Compound A23)
Affinity DataIC50: 14.8nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606919(US11685738, Compound A28 | acid )
Affinity DataIC50: 16.9nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606918(US11685738, Compound A24 | acid )
Affinity DataIC50: 17.5nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM50134778((S)-3-(6-Methoxy-pyridin-3-yl)-3-{2-oxo-3-[3-(5,6,...)
Affinity DataIC50: 17.6nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606867(US11685738, Compound A3)
Affinity DataIC50: 18.2nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606865(US11685738, Compound A4)
Affinity DataIC50: 21.4nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606883(US11685738, Compound A6)
Affinity DataIC50: 24nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606919(US11685738, Compound A28 | acid )
Affinity DataIC50: 34.4nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606918(US11685738, Compound A24 | acid )
Affinity DataIC50: 35.4nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606955(US11685738, Compound A21-2)
Affinity DataIC50: 50.3nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606881(US11685738, Compound A5)
Affinity DataIC50: 63.9nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606881(US11685738, Compound A5)
Affinity DataIC50: 65.7nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606866(US11685738, Compound A2)
Affinity DataIC50: 78.1nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606867(US11685738, Compound A3)
Affinity DataIC50: 79.3nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606884(US11685738, Compound A7)
Affinity DataIC50: 80.6nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606954(US11685738, Compound A21 | acid )
Affinity DataIC50: 88.2nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-8(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606917(US11685738, Compound A23)
Affinity DataIC50: 151nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606883(US11685738, Compound A6)
Affinity DataIC50: 190nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent